Last reviewed · How we verify
ALUMINUM PHOSPHATE
Aluminum Phosphate is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and long-standing use. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | ALUMINUM PHOSPHATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults (PHASE1)
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (PHASE1)
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (PHASE4)
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults (PHASE1, PHASE2)
- Diode Laser-Assisted Periodontal Therapy Enhances Clinical Outcomes for Deep Periodontal Pockets in Smokers (NA)
- HIV Vaccine in HIV-uninfected Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALUMINUM PHOSPHATE CI brief — competitive landscape report
- ALUMINUM PHOSPHATE updates RSS · CI watch RSS